Blood compatibility of polyamidoamine dendrimers and erythrocyte protection

Journal of Biomedical Nanotechnology

Volumn 6, Issue 1, 2010, Pages 82-92

  Han, Mei Hua ^a   Chen, Jing ^b   Wang, Jian ^c   Chen, Shi Lin ^a   Wang, Xiang Tao ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^b HARBIN UNIVERSITY OF COMMERCE   (China)

^c HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Blood compatibility; Cytotoxicity; Haemolysis; PAMAM dendrimers; RBC aggregation

Indexed keywords

AMINO GROUP; BIOMEDICAL APPLICATIONS; BLOOD COMPATIBILITY; CHARGED MOLECULE; COMPLEX FORMATIONS; HAEMOLYSIS; PAMAM DENDRIMER; PH ADJUSTMENT; PLASMA PROTEIN; POLYAMIDOAMINE DENDRIMERS; POLYMERIC STRUCTURES; RED BLOOD CELL; SURFACE FUNCTIONAL GROUPS; TIME COURSE; TIME DEPENDENT; WHOLE BLOOD;

BIOCOMPATIBILITY; BLOOD; BLOOD SUBSTITUTES; CARBOXYLIC ACIDS; DENDRIMERS; DYES; FUNCTIONAL GROUPS; ORGANIC ACIDS; PLASMAS; PROTEINS;

FUNCTIONAL POLYMERS;

CARBOXYLIC ACID; DENDRIMER; FUNCTIONAL GROUP; PLASMA PROTEIN; POLYAMIDOAMINE; BIOMATERIAL; CATION; PAMAM STARBURST;

ARTICLE; BIOCOMPATIBILITY; BLOOD COMPATIBILITY; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN EXPERIMENT; MACROMOLECULE; MORPHOLOGY; NORMAL HUMAN; PH; PLASMA; POLYMERIZATION; SOLUTION AND SOLUBILITY; CELL CULTURE; CELL LINE; CELL SHAPE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; IC 50; MATERIALS TESTING; METABOLISM; MICROSCOPY;

BIOCOMPATIBLE MATERIALS; CATIONS; CELL LINE; CELL SHAPE; CELL SURVIVAL; CELLS, CULTURED; DENDRIMERS; ERYTHROCYTES; HEMOLYSIS; HUMANS; INHIBITORY CONCENTRATION 50; MATERIALS TESTING; MICROSCOPY;

EID: 77954043891     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1096     Document Type: Article

References (32)

1. D. A. Tomalia, B. Huang, D. R. Swanson, H. M. Brothers, and J. W. Klimash, Structure control within poly(amidoamine) dendrimers: Size, shape and regio-chemical mimicry of globular proteins. Tetrahedron 59, 3799 (2003).
2. R. W. J. Scott, O. M. Wilson, and R. M. Crooks, Synthesis, characterization, and applications of dendrimer - Encapsulated nanoparticles. J. Phys. Chem. B 109, 692 (2005).
3. C. Dufes, I. F. Uchegbu, and A. G. Schatzlein, Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 57, 2177 (2005).
4. U. Boas and P. M. H. Heegaard, Dendrimers in drug research. Chem. Soc. Rev. 33, 43 (2004).
5. H. Yang and W. Y. J. Kao, Dendrimers for pharmaceutical and biomedical applications. Journal of Biomaterials Science-Polymer Edition 17, 3 (2006).
6. D. A. Tomalia, Dendrimer molecules. Scientific American 272, 62 (1995).
7. A. K. Patri, J. F. Kukowska-Latallo, and J. R. Baker, Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev. 57, 2203 (2005).
8. Y. Cheng and T. Xu, The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs. European Journal of Medicinal Chemistry 43, 2291 (2008).
9. C. Kojima, K. Kono, K. Maruyama, and T. Takagishi, Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 11, 910 (2000).
10. G. Wu, R. F. Barth, W. Yang, S. Kawabata, L. Zhang, and K. Green-Church, Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5, 52 (2006).
11. W. G. Lesniak, M. S. Kariapper, B. M. Nair, W. Tan, A. Hutson, L. P. Balogh, and M. K. Khan, Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting alphavbeta3 integrins. Bioconjugate Chem. 18, 1148 (2007).
12. R. F. Barth, D. M. Adams, A. H. Soloway, F. Alam, and M. V. Darby, Boronated starburst-monoclonal antibody immuno-conjugates: Evaluation as a potential delivery system for neutron captures therapy. Bioconjugate Chem. 5, 58 (1994).
13. W. L. Yang, R. F. Barth, D. M. Adams, and A. H. Solway, In-tratumoural delivery of boronated epidermal growth factor for neutron capture therapy for brain tumours. Cancer Res. 57, 4333 (1997).
14. J. Sakamoto and K. Mullen, Sugars within a hydrophobic scaffold: Glycodendrimers from polyphenylenes. Org. Lett. 6, 4277 (2004).
15. M. Longmire and P. L. Choyke, Dendrimer-based contrast agents for molecular imaging. Curr. Top. Med Chem. 8, 1180 (2008).
16. N. Joshi and M. Grinstaff, Applications of dendrimers in tissue engineering. Curr. Top. Med Chem. 8, 1225 (2008).
17. R. Duncan and L. Izzo, Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57, 2215 (2005).
18. D. Fischer, Y. X. Li, B. Ahlemeyer, J. Krieglstein, and T. Kissel, In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and haemolysis. Biomaterials 24, 1121 (2003).
19. R. Jevprasesphant, J. Penny, D. Attwood, N. B. McKeown, and A. D'Emanuele, Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 20, 1543 (2003).
20. H. T. Chen, M. F. Neerman, A. R. Parrish, and E. E. Simanek, Cytotoxicity, haemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 126, 10044 (2004).
21. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, and J. W. Weener, Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-labelled polyamidoamine dendrimers in vivo. J. Control Release 65, 133 (2000).
22. R. Jevprasesphant, J. Penny, R. Jalal, D. Attwood, N. B. McKeown, and A. D'Emanuele, The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252, 263 (2003).
23. S. Fuchs, T. Kapp, H. Otto, T. Schoneberg, P. Franke, R. Gust, and A. D. Schluter, A surface-modified dendrimer set for potential application as drug delivery vehicles: Synthesis, in vitro toxicity, and intracellular localization. Chem.-A Eur. J. 10, 1167 (2004).
24. H. R. Ihre, O. L. P. De Jesus, F. C. Szoka, and J. M. J. Frechet, Polyester dendritic systems for drug delivery applications: Design, synthesis, and characterization. Bioconjug. Chem. 13, 443 (2002).
25. D. M. Domanski, B. Klajnert, and M. Bryszewska, Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 63, 189 (2004).
26. S. Sonke, Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharma 71, 445 (2008).
27. D. Sgouras and R. Duncan, Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential for biomedical use: 1. Use of the tetrazolium-based colorimetric assay (MTT) as a preliminary screen for the evaluation of in vitro cytotoxicity. J. Mater. Sci. Med 1, 67 (1990).
28. R. Duncan, M. Bhakoo, M.-L. Riley, and A. Tuboku-Metzger, Soluble polymeric drug carriers: Haematocompatibility, Progress in Membrane Biotechnology, edited by J. C. Gomez-Fernandez, D. Chapman and L. Packer, Birkhäuser Verlag, Basel (1991), p. 253.
29. J. C. Roberts, M. K. Bhalgat, and R. T. Zera, Preliminary biological evaluation of polyamidoamine (PAMAM) starburstk dendrimers. J. Biomed Mater. Res. 30, 53 (1996).
30. H. Yoo and R. L. Juliano, Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res. 28, 4225 (2000).
31. W. Wang, W. Xiong, J. Wan, X. Sun, H. Xu, and X. Yang, The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress. Nanotechnology 20, 105103 (2009).
32. C. F. Jones and D. W. Grainger, In vitro assessments of nanomaterial toxicity. Advanced Drug Delivery Reviews 61, 438 (2009).